The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the ...

EMERYVILLE, CA--(Marketwired - January 07, 2016) - 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced ...

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

- Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9 - - Fabry product candidate, 4D-310, is on track for anticipated clinical trial initiation in ...

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one ...